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Genomic alterations of ribosomal protein genes in diffuse
large B cell lymphoma
Ribosomal biogenesis (the process of building new ribosomes
for protein synthesis), is frequently altered in cancer. Current
evidence suggests that ribosomal biogenesis is involved in
different processes other than protein synthesis, acting as a
dynamic stress sensor regulating cell cycle and apoptosis
through modulation of p53 activity (Bursac et al, 2014).
Genomic screening has recently identified copy number
alterations and somatic mutations of ribosomal proteins
(RPs) in haematological malignancies such as acute lym-
phoblastic leukaemia, chronic lymphocytic leukaemia (CLL)
and multiple myeloma (MM) (reviewed in Sulima et al,
2017). In the present study we analysed public datasets con-
taining whole exome sequencing data from multiple studies
on mature lymphoid B cell malignancies using the cBioportal
website analysis tool (Cerami et al, 2012), focusing on geno-
mic alterations of ribosomal protein genes (n = 80) and the
TP53 gene (which encodes the p53 protein). Copy number
variants (CNV) data were available only for DLBCL [The
Cancer Genome Atlas (TCGA) provisional dataset; http://
www.cbioportal.org/study?id=dlbc_tcga#summary]. We ini-
tially evaluated 7 studies (n = 1016 patients) including
DLBCL [3 studies: TCGA provisional dataset + (Lohr et al,
2012 and Braggio et al, 2015) (n = 116 patients)], Mantle
cell lymphoma (Bea et al, 2013; 29 patients), MM (Lohr
et al, 2014; 205 patients), CLL (Landau et al, 2013; Puente
et al, 2015; 2 studies, 666 patients).
Genomic alterations of RPs occurred at low frequency in
4% of analysed samples (n = 42) (Fig 1A). The only RPs
found to be mutated in more than one patient were RPL3
(n = 3), RPL4 (n = 2), RPL10 (n = 3), RPL10A (n = 2),
RPL13 (n = 4), RPSA (n = 2), RPS2 (n = 2), RPS9 (n = 2),
RPS16 (n = 2), FAU (n = 3) (Fig 1A). RP gene mutations
were found in DLBCL, CLL and MM and were predomi-
nantly missense. Mutations of RPs belonging to the large
ribosomal subunit were predominant in DLBCL and MM,
whereas CLL was characterized by a higher frequency of
mutations of the small ribosomal subunit (Fig 1B). Notably,
DLBCL showed the highest frequency of RP genomic alter-
ations (Fig 1C). More precisely, we identified non-recurrent
mutations of 13 different RP genes in 14 (12%) of 116
DLBCL patients (Fig 1D). RPL3, RPL13 and FAU were the
only RP genes mutated in more than one DLBCL patient
sample (2 samples each, 17%). Of note, FAU mutations
affected the ubiquitin-like protein FUBI at the N terminus,
sparing the RPS30 protein. Affected genes and mutations are
summarized in Table I. Residues involved in RPL3 and
RPL13 mutations are depicted in Fig 1E. Overall, there was a
tendency towards a mutual exclusivity of RP gene mutations,
Fig 1. (A) Heat map showing RP mutations in 7 patient cohorts including 1016 patients affected by lymphoproliferative disorders (116 DLBCL,
205 MM, 29 MCL, 666 CLL patients). Each row represents a gene, each column represents a patient. (B) Charts showing the fraction of samples
harbouring mutated RPs in each disease type (left), and the fraction of cases harbouring mutations of the large versus small ribosomal subunit
RP genes (right). (C) Bar graph showing the incidence of RPs mutations across different B cell lymphoid malignancies, demonstrating signifi-
cantly higher frequency in DLBCL. **P value <001, chi-square test. (D) Heat map showing RP mutations in 3 patient cohorts including 116
DLBCL patients. Each row represents a gene, each column represents a patient. (E) Linear view of the RPL3 and RPL13 mutations found in the
DLBCL datasets. (F) Heat map showing TP53, RP gene mutations and RPS12 deletions in the TCGA dataset (n = 48 patients). (G) Chart showing
the proportion of RPS12-deleted patients in our validation cohort (DLCL04 study), (upper panel). Mutual exclusivity of RPS12 deletions and
TP53 mutations in the DLCL04 study (lower panel). (H) Bar graph showing the proportion of patients who had died in the RP mutant versus
RP wild-type groups. FAU mutations sparing the RPS30 gene were not considered in this analysis. The analysis was restricted to TP53 wild-type
patients. **P value <001, chi-square test. (I) Western blot showing the effect of RPS12 silencing by ShRNAs on P53 stabilization after treatment
with doxorubicin in DOHH2 cells. Cells infected with scramble (SCR) and RPS12 ShRNAs (Sh1 and Sh2) were pre-treated with doxycycline
01 lmol/l for 48 h in order to induce RPS12 silencing and then incubated with DMSO or doxorubicin 100 nmol/l for 6 h: P53 levels before and
after treatment were then detected by Western blot assay. CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B cell lymphoma; DMSO,
dimethyl sulphoxide; DOXO, doxorubicin; MCL, mantel cell lymphoma; MM, multiple myeloma; RP, ribosomal protein.
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as only 2 of 14 patients (14%) showed concomitant muta-
tions of multiple RPs (Fig 1D).
At the time of this analysis, genome wide CNV data were
available only in the TCGA provisional dataset (48 samples)
(Fig 1F). We found losses of the RPL22 and RPS12 genes in
4 (8%) and 5 (10%) of 48 cases respectively. Due to the nov-
elty, we focused on CNVs of the RPS12 gene (Fig 1G–I),
which is located on 6q23.2. To validate these findings, we
performed genome-wide copy number analysis in an inde-
pendent cohort of 57 DLBCL patients enrolled in a prospec-
tive clinical trial (DLCL04) (Chiappella et al, 2017), using
the OncoScan(TM) assay. The RPS12 gene was deleted in 12
(21%) of 57 samples (Fig 1G), being involved in 75% of
cases (12/16) with 6q23 deletion. These findings indicate that
RPS12 loss is a common genetic event in DLBCL. Consider-
ing the TCGA provisional dataset, the cumulative incidence
of RP mutations/RPS12 deletions was 29% (14 of 48 cases)
(Fig 1F).
Given that multiple RPs have been shown to regulate
p53 stability in response to nucleolar stress by modulating
murine double minute 2 (MDM2)-p53 interactions (Bursac
et al, 2014), we investigated the relationship between RP
genomic alterations and the presence of TP53 mutations in
DLBCL. Interestingly RP mutations in all DLBCL cohorts
were mutually exclusive with TP53 mutations (Fig 1D). A
similar trend was observed with RPS12 losses (TCGA pro-
visional cohort) (Fig 1F). To validate these observations,
we performed TP53 DNA Sanger sequencing of the
DLCL04 cohort, confirming mutual exclusivity between
RPS12 losses and TP53 mutations (Fig 1G). Restricting the
analysis to patients with available survival data (TCGA
cohort), we observed a statistically higher death rate in
TP53 wild-type patients harbouring RP mutations com-
pared to those without RP mutations (Fig 1H). These data
suggest that mutations of RPs could provide lymphoma
cells with an alternative mechanism to inactivate the p53-
mediated response upon nucleolar stress. On the contrary,
we did not observe significant differences in outcome
between RPS12 deleted and wild-type patients in the
DLCL04 cohort (data not shown). In line with this obser-
vation, RPS12 silencing did not have a significant impact
on p53 stabilization after treatment with doxorubicin in a
TP53 wild-type DLBCL cell line (Fig 1I).
This report describes, for the first time, genomic alter-
ations of RP genes in a significant fraction of DLBCL cases.
Although the functional and clinical consequences of these
RP alterations are yet to be determined, these preliminary
observations suggest a possible correlation with adverse out-
come, which should be investigated in future studies. This
notion could be highly significant as many of the currently
used chemotherapeutic drugs (such as doxorubicin) are
indeed inhibitors of ribosomal biogenesis (reviewed in Bursac
et al, 2014), and drugs selectively targeting ribosomal biogen-
esis are now in clinical development for haematological
malignancies. Finally, the observation that both RP muta-
tions and RPS12 losses were mutually exclusive with TP53
mutations might imply a role for these RP changes in neo-
plastic transformation.
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Table I. Genomic alterations of RP genes in DLBCL.
Gene Chromosome Mutation type Amino acid change Outcome Study (Reference)
RPL3 22 Missense
Missense
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(Lohr et al, 2012)
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Stage I Non-Hodgkin Lymphoma: difference in survival
outcome by primary extranodal site of involvement
Lymphoma can develop in any organ or tissue. The percent-
age of patients presenting with localized disease (Ann Arbor
stage I/II) differs by histological subtype may arise in nodal
and/or involve other organs or tissues (extranodal). Although
certain primary sites have been demonstrated to reflect dis-
tinct clinicopathological characteristics and require specific
therapy [e.g. primary central nervous system (PCNSL), pri-
mary testicular lymphoma and primary mediastinal lym-
phoma] (Cheah et al, 2014; Dunleavy, 2017; Grommes &
DeAngelis, 2017), aside from these examples there are limited
data to suggest other extranodal sites have prognostic impli-
cations. Therefore, we evaluated the survival outcome of
patients with stage I non-Hodgkin lymphoma (NHL) among
different histological subtypes, focusing on evaluating the dif-
ferences in survival outcome by primary site of involvement.
The Surveillance, Epidemiology and End Results (SEER)
18 database (https://seer.cancer.gov/) was used to evaluate
overall survival (OS) of patients with stage I NHL by differ-
ent primary site of involvement in patients aged ≥18 years
diagnosed between 1998 and 2014. We excluded lymphomas
that develop exclusively in extranodal sites, such as PCNSL,
primary mediastinal lymphoma, testicular lymphoma, cuta-
neous T cell lymphoma, primary effusion lymphoma, extran-
odal Natural Killer cell lymphoma, enteropathy associated T
cell lymphoma (EATL) and hepatosplenic T cell lymphoma
(HSTL). OS was calculated from diagnosis to death from any
cause using the Kaplan-Meier method. Cox proportional haz-
ards models were used to evaluate associations between
patient characteristics and survival. All analyses were per-
formed using STATA version 13.1 (StataCorp LP, College
Station, TX), with significance set at the 5% level.
After excluding diseases as described above, a total of
58 230 patients were diagnosed with stage I disease during the
study period (Table I). With a median follow-up of 68 months
(range: 1–203 months), the median OS of patients with diffuse
large B cell lymphoma (DLBCL), follicular lymphoma (FL),
marginal zone lymphoma (MZL), small lymphocytic lym-
phoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma
(MCL) and peripheral T cell lymphoma (PTCL, including
PTCL-not otherwise specified, angioimmunoblastic T cell
lymphoma and anaplastic large cell lymphoma) was 120, 179,
165, 101, not reached, 70 and 109 months, respectively.
Hazard ratios (HR) for OS by multivariate analysis,
adjusted for age, sex, race and treatment (classified as none,
radiation alone, chemotherapy alone and chemo-radiation), in
stage I extranodal disease compared to stage I nodal disease of
the same histological subtype are summarized in Table II. The
5-year OS of each site by histological subtypes is summarized
in Table SI. Overall, compared to nodal stage I disease, extran-
odal stage I disease trended towards longer survival in MZL
and FL but was associated with shorter survival in PTCL.
The study showed that survival outcomes among patients
with stage I NHL are influenced by specific extranodal site of
involvement. Compared to nodal disease, cutaneous disease
was associated with significantly longer OS in all subtypes
except BL and MCL, breast disease was associated with sig-
nificantly longer OS in FL and SLL, and colonic disease was
associated with significantly longer OS in FL, SLL, MZL and
MCL. In contrast, gastric and bone disease was associated
with inferior OS in FL, BL and PTCL.
Extranodal stage I disease was generally associated with
longer OS in FL and MZL but shorter OS in PTCL. Nodal
MZL has different biology compared to extranodal MZL and
is associated with shorter OS compared to extranodal disease
(Swerdlow et al, 2008). In contrast, extranodal disease, such
as in lung, pleura, stomach, small intestine, liver and bone dis-
ease, was associated with shorter OS in PTCL. Interestingly,
skin (DLBCL, FL, SLL, MZL and PTCL), colon (FL, SLL,
MZL and MCL) and breast (FL and SLL) disease were associ-
ated with significantly longer OS across several subtypes. In
addition to possible biological difference in lymphomas at
those sites, these are the sites routinely screened for other can-
cers (breast and colon) or can be easily found by patients
(skin) and thus may have been detected earlier, resulting in a
more favourable clinical condition and prognosis.
The prognostic implications of extranodal disease have
been evaluated in other studies, mostly in DLBCL (Moller
et al, 2004; Lopez-Guillermo et al, 2005; Hui et al, 2010;
Castillo et al, 2014). Castillo et al (2014) analysed the impact
of extranodal involvement in patients with DLBCL using
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